IJMSPH

International Journal of Medical Science and Public Health

« Previous Article
Next Article »

Original Research Open Access


Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML)

L P Meena, J Prakash, R Tandon, Anju Bharti, V K Meena, K Tripathi.

Abstract
Background : VEGF play a significant role in the pathogenesis of chronic myeloid leukemia .

Objective :(1).Assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). (2). Study the effect of Hydroxyurea and Imatinib on serum VEGF level.

Material and Methods : A total of 40 cases of chronic myeloid leukemia (CML) and 20 age and sex matched healthy controls were included in this study. The patients were divided into three subcategory: Untreated cases (which did not receive any treatment);patients who were treated with Hydroxyurea and patients who were treated with Imatinib Mesylate . 5 ml of blood was collected , were centrifuged at 5000 rpm for 10 minutes and stored at - 20C until assay.

Results : On comparing the various subgroups with control, the values was 726.61 199.67 pg/ml in Untreated group. It was 573.53 213.423 pg/ml in Hydroxyurea group and 530.00180.96 pg/ml in Imatinib group. Fresh cases had significantly elevated VEGF value (P value < 0.001) . VEGF level significantly elevated in Untreated cases when compared to treated groups either hydroxyurea (p=0.02) or Imatinib (p=0.019). There was no significant difference between Hydroxyurea and Imatinib groups.

Conclusion : This study suggest that VEGF play a significant role in the pathogenesis of chronic myeloid leukemia. Understanding this may help in designing new therapeutic strategies(antiangiogenic agents) for this dreaded disease.

Key words: VEGF,CML, Imatinib, Hydroxyurea


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by L P Meena
Articles by J Prakash
Articles by R Tandon
Articles by Anju Bharti
Articles by V K Meena
Articles by K Tripathi
on Google
on Google Scholar
Article Statistics
 Viewed: 2042
Downloaded: 710
Cited: 0

REFERENCES
1. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF. Science 1999; 284: 199498.

http://dx.doi.org/10.1126/science.284.5422.1994

[Pubmed]   

2. Hicklin DJ, Ellis LM. Review: Role of VEGF in tumour growth and angiogenesis. J ClinOncol .2005; 23:1011-1027.

http://dx.doi.org/10.1200/JCO.2005.06.081

[
Pubmed]   

3. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of humancolon cancer. Cancer Res .1995; 55:3964-3968.

[
Pubmed]   

4. Ellis LM, Takahashi Y, Wenbiao L, et al. Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications. The Oncologist.2000; 5 (suppl 1):11-15.

http://dx.doi.org/10.1634/theoncologist.5-suppl_1-11

[
Pubmed]   

5. Yoshiji H, Gomez D, Shibuya E. et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res .1996; 56:201316.

[
Pubmed]   

6. Podar K, Anderson K therapeutic implications. The pathophysiologic role of VEGF in hematologic malignancies: Blood .2005; 105: 1383-1395.

http://dx.doi.org/10.1182/blood-2004-07-2909

[
Pubmed]   

7. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies Critical review in oncology/ hematology .2007; 62: 105- 118.

http://dx.doi.org/10.1016/j.critrevonc.2006.11.006

[
Pubmed]   

8. Dietmar W, David J et al. Vascular-Targeting Therapies for Treatment of Malignant Disease; Cancer .2004; 100 (12): 2491-2499.

http://dx.doi.org/10.1002/cncr.20299

[
Pubmed]   

9. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist .2004; 9(Suppl. 1):210.

http://dx.doi.org/10.1634/theoncologist.9-suppl_1-2

[
Pubmed]   

10. Rosen L. Antiangiogenic Strategies and Agents in Clinical Trials. The Oncologist .2000;5(1): 20-27.

http://dx.doi.org/10.1634/theoncologist.5-suppl_1-20

[
Pubmed]   

11. Hagop M. Kantarjian, Moshe T et al . New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. Ann Intern Med.2006; 145:913-923.


12. Hicklin DJ, Ellis LM. Review: Role of VEGF in tumor growth and angiogenesis. JClin Oncol.2005; 23:1011-1027.

http://dx.doi.org/10.1200/JCO.2005.06.081

[
Pubmed]   

13. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of humancolon cancer. Cancer Res.1995; 55:3964-3968.

[
Pubmed]   

14. Wellmann S, Guschmann M Griethe W et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF, Leukemia 2004;18 (5), 926933.

http://dx.doi.org/10.1038/sj.leu.2403332

[
Pubmed]   

15. Faderl S, Do K A, Johnson M et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia, Blood .2005;106 (13), 43034307.

http://dx.doi.org/10.1182/blood-2005-03-1010

[
Pubmed]   

16. Diffner E, Gauffin F, Anagnostaki L, Nordgren A, Gustafsson B, Sander B, et al . Expression of VEGF and VEGF receptors in childhood precursor B-cell acute lymphoblastic leukemia evaluated by immunohistochemistry J PediatrHematol Oncol.2009; Sep;31(9):696-701.

http://dx.doi.org/10.1097/MPH.0b013e3181b258df

[
Pubmed]   

17. Michael Medinger, Natalie Fischer, AlexandarTzankov. Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies Journal of Oncolgy.2010; [DOI via Crossref]   
http://dx.doi.org/10.1155/2010/729725


18. Legros L, Bourcier C and Jacquel A et al . Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia, Blood 2004;104 (2): 495501.

http://dx.doi.org/10.1182/blood-2003-08-2695

[
Pubmed]   

19. Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces Bcr-Abl mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1:89-95.

[
Pubmed]   

20. PengL,Jian Y, Lia Z, et al . Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia & Lymphoma, Leuk Lymphoma.2005; 46(12): 1761 1764.

http://dx.doi.org/10.1080/10428190500262318

[
Pubmed]   

21. Verstovsek S, Kantarjian H and Manshouri T et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia, Blood 2002; 99(6) : 22652267.

http://dx.doi.org/10.1182/blood.V99.6.2265

[
Pubmed]   

22. Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol .2002;157: 1519.

http://dx.doi.org/10.1016/S0002-9440(10)64511-7


23. Alvaro A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute & chronic leukemias&myelodysplastic syndromes. Blood.2000; 96:2240-2245.


24. Janowska-Wieczorek A, Majka M, Marquez-Curtis L,et al . Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia .2002;16:1160 1166

http://dx.doi.org/10.1038/sj.leu.2402486

PMid:12040448

How to Cite this Article
Pubmed Style

Meena LP, Prakash J, Tandon R, Bharti A, Meena VK, Tripathi K. Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). Int J Med Sci Public Health. 2013; 2(1): 48-51. doi:10.5455/ijmsph.2013.2.48-51



Web Style

Meena LP, Prakash J, Tandon R, Bharti A, Meena VK, Tripathi K. Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). www.scopemed.org/?mno=26679 [Access: November 19, 2017]. doi:10.5455/ijmsph.2013.2.48-51



AMA (American Medical Association) Style

Meena LP, Prakash J, Tandon R, Bharti A, Meena VK, Tripathi K. Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). Int J Med Sci Public Health. 2013; 2(1): 48-51. doi:10.5455/ijmsph.2013.2.48-51



Vancouver/ICMJE Style

Meena LP, Prakash J, Tandon R, Bharti A, Meena VK, Tripathi K. Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). Int J Med Sci Public Health. (2013), [cited November 19, 2017]; 2(1): 48-51. doi:10.5455/ijmsph.2013.2.48-51



Harvard Style

Meena, L. P., Prakash, J., Tandon, R., Bharti, A., Meena, V. K. & Tripathi, K. (2013) Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). Int J Med Sci Public Health, 2 (1), 48-51. doi:10.5455/ijmsph.2013.2.48-51



Turabian Style

Meena, L P, J Prakash, R Tandon, Anju Bharti, V K Meena, and K Tripathi. 2013. Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). International Journal of Medical Science and Public Health , 2 (1), 48-51. doi:10.5455/ijmsph.2013.2.48-51



Chicago Style

Meena, L P, J Prakash, R Tandon, Anju Bharti, V K Meena, and K Tripathi. "Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML)." International Journal of Medical Science and Public Health 2 (2013), 48-51. doi:10.5455/ijmsph.2013.2.48-51



MLA (The Modern Language Association) Style

Meena, L P, J Prakash, R Tandon, Anju Bharti, V K Meena, and K Tripathi. "Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML)." International Journal of Medical Science and Public Health 2.1 (2013), 48-51. Print. doi:10.5455/ijmsph.2013.2.48-51



APA (American Psychological Association) Style

Meena, L. P., Prakash, J., Tandon, R., Bharti, A., Meena, V. K. & Tripathi, K. (2013) Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia(CML). International Journal of Medical Science and Public Health , 2 (1), 48-51. doi:10.5455/ijmsph.2013.2.48-51



latest news

Retraction notice [Dec 03, 2016]
Retraction notice [Mar 02, 2015]
Submission of article [Jul 22, 2012]


The articles in this Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.